Find the latest Revenue (TTM) for Bellerophon Therapeutics, Inc. (BLPH) The Style Scores are a … Bellerophon Therapeutics Inc. (NASDAQ: BLPH) stock closed at 7.1 per share at the end of the most recent trading day (a -1.25 % change compared to the prior day closing price) with a volume of 28.59K shares and market capitalization of 67.44M.. Bellerophon Therapeutics General Information Description Bellerophon Therapeutics Inc is a clinical-stage biotherapeutics company. Tip: Try a valid symbol or a specific company name for relevant results Revenue (TTM) is a widely used stock evaluation measure. Find out the revenue, expenses and profit or loss over the last fiscal year. Bellerophon Therapeutics (BLPH) Reports Q3 Loss, Lags Revenue Estimates Bellerophon Therapeutics (BLPH) delivered earnings and revenue surprises of -2.44% and -100.00%, respectively, for the quarter ended September 2020. View Bellerophon Therapeutics (www.bellerophon.com) location in New Jersey, United States , revenue, industry and description. Given Bellerophon Therapeutics' higher probable upside, equities research analysts plainly believe Bellerophon Therapeutics is more favorable than Tiziana Life Sciences. 8:17a Oil prices extend gains, amid sluggish return of … London retains title of most popular city for work Despite Brexit Bellerophon Therapeutics stock was originally listed at a price of $134.55 in Feb 13, 2015. Stock Price Statistics The stock price has decreased by -6.26% in the last 52 Company profile for Bellerophon Therapeutics Inc. including key executives, insider trading, ownership, revenue and average growth rates. Find the latest Revenue & EPS data for Bellerophon Therapeutics, Inc. Common Stock (BLPH) at Nasdaq.com. Bellerophon Therapeutics (BLPH) delivered earnings and revenue surprises of -2.44% and -100.00%, respectively, for the quarter ended September 2020. View BLPH financial statements in full. Annual stock financials by MarketWatch. According to present data Bellerophon Therapeutics's BLPH shares and potentially its market environment have … Tip: Try a valid symbol or a specific company name for Bellerophon Therapeutics (BLPH) came out with a quarterly loss of $0.84 per share versus the Zacks Consensus Estimate of a loss of $0.82. Bellerophon Therapeutics net income from 2013 to 2020. © Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. View detailed BLPH description & address. See Bellerophon Therapeutics, Inc. (BLPH) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. Exhibit 99.1 Bellerophon Therapeutics Announces FDA Clears Initiation of Phase 3 Study for INOpulse® Inhaled Nitric Oxide Therapy to Treat COVID-19 WARREN, N.J., May 11, 2020 - Bellerophon Therapeutics, Inc. (Nasdaq Bellerophon Therapeutics Bellerophon's focus is the continued development of its nitric oxide therapy for patients with pulmonary hypertension, or PH, using its proprietary delivery system, INOpulse, with pulmonary arterial hypertension, or PAH, representing the lead indication. Get the detailed quarterly/annual income statement for Bellerophon Therapeutics, Inc. (BLPH). EPS of -$0.86 beats by $0.04 | Revenue of $0.00 (- Y/Y) beats by $0.00 The following slide deck was published by Bellerophon Therapeutics, Inc. in conjunction with this event. Bellerophon Therapeutics Submits Investigational New Drug Application to Study INOpulse® Inhaled Nitric Oxide Therapy for the Treatment of COVID-19 - Yahoo Finance The Daily Biotech Pulse: LogicBio Slapped With Clinical Hold Bellerophon Therapeutics Inc. www.barrons.com - May 7 at 12:55 AM Bellerophon Therapeutics to Participate in COVID-19 Panel at Maxim Group’s Infectious Disease Virtual Conference finance.yahoo.com - May 4 at 6:12 PM Bellerophon Therapeutics (BLPH) Reports Q3 Loss, Lags Revenue Estimates Bellerophon Therapeutics (BLPH) delivered earnings and revenue surprises of -2.44% and -100.00%, respectively, for the quarter ended September 2020. Bellerophon Therapeutics, Inc. is a clinical-stage therapeutics company. Wall Street Stock Market & Finance report, prediction for the future: You'll find the Bellerophon Therapeutics share forecasts, stock quote and buy / sell signals below.. Do the numbers hold clues to what lies ahead for the stock? Bellerophon Therapeutics Inc. View the latest BLPH financial statements, income statements and financial ratios. Bellerophon Therapeutics: A Promising Solution To America's Ventilator Shortage During The COVID-19 Pandemic Apr. View as PDF Bellerophon Therapeutics Inc Key Recent Developments Nov 07,2018: Bellerophon provides business update and reports third quarter 2018 financial results Bellerophon Therapeutics Inc. company facts, information and financial ratios from MarketWatch. Bellerophon Therapeutics is headquartered in Warren, New Jersey, the US. Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and p Detailed statistics for Bellerophon Therapeutics (BLPH) stock, including valuation metrics, financial numbers, share information and more. Bellerophon Provides Clinical Program Update and Reports Third Quarter 2020 Financial Results WARREN, N.J., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary and infectious diseases, today provided a clinical … Get the latest Bellerophon Therapeutics Inc earnings report, revenues as well as upcoming BLPH earnings dates, historical financial reports, news, analysis & more. In depth view into Bellerophon Therapeutics Revenue (Quarterly) including historical data from 2015, charts, stats and industry comps. Find related and similar companies as … Stock analysis for Bellerophon Therapeutics Inc (BLPH:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile. If you had invested in Bellerophon Therapeutics stock at $134.55, your return over the last 6 years would have been -95.02%, for an. Sector Industry Market Cap Revenue … Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for. Find out all the key statistics for Bellerophon Therapeutics, Inc. (BLPH), including valuation measures, fiscal year financial statistics, trading record, share statistics and more. Bellerophon Therapeutics Inc. balance sheet, income statement, cash flow, earnings & estimates, ratio and margins. Bellerophon Therapeutics Inc () Stock Market info Recommendations: Buy or sell Bellerophon Therapeutics stock? Valuation and Earnings This table compares Bellerophon Therapeutics and Tiziana Life Sciences' gross revenue, earnings per share and valuation.